Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study

Diabetes and dyslipidemia are leading causes of mortality and morbidity. According to international guidelines, statins are the cornerstone of treatment in patients with diabetes and/or dyslipidemia. However, statins and antidiabetic agents have opposite pharmacological effects, because statins, par...

Full description

Saved in:
Bibliographic Details
Published in:Yonsei medical journal 2023, 64(3), , pp.175-180
Main Authors: Tarim, Bahar Arican, Fici, Francesco, Tengiz, Istemihan, Avunduk, Saadet, Ozcan, Yurdaer, Faikoglu, Gokhan, Ari, Elif, Robles, Nicolás Roberto, Grassi, Guido
Format: Article
Language:English
Subjects:
Atorvastatin - therapeutic use
Cholesterol, LDL - therapeutic use
Diabetes Mellitus, Type 2 - drug therapy
Dyslipidemias - drug therapy
Glucose
Glycated Hemoglobin
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hypoglycemic Agents - therapeutic use
Original
Prospective Studies
Pyrroles - therapeutic use
Rosuvastatin Calcium - therapeutic use
Treatment Outcome
의학일반
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetes and dyslipidemia are leading causes of mortality and morbidity. According to international guidelines, statins are the cornerstone of treatment in patients with diabetes and/or dyslipidemia. However, statins and antidiabetic agents have opposite pharmacological effects, because statins, particularly atorvastatin and rosuvastatin, impair glucose homeostasis, increasing the risk of new-onset diabetes, whereas antidiabetic drugs improve glycemic homeostasis. The aim of this study was to investigate the effect of atorvastatin, rosuvastatin, and pitavastatin on glucose homeostasis in patients with type 2 diabetes mellitus (T2DM) and dyslipidemia during stable treatment with hypoglycemic drugs. The study was conducted as a pilot, prospective, randomized, open label, parallel group with blinded-endpoints (PROBE) study. Of 180 recruited patients with T2DM and dyslipidemia, 131 were randomized to atorvastatin (n=44), rosuvastatin (n=45), and pitavastatin (n=42) and treated for 6 months. Fasting plasma glucose (FPG) marginally decreased in patients assigned to atorvastatin (-3.5 mg/dL, =0.42) and rosuvastatin (-6.5 mg/dL, =0.17), while it decreased much more in patients treated with pitavastatin (-19.0 mg/dL,
ISSN:0513-5796
1976-2437
DOI:10.3349/ymj.2022.0287